01 January 2008
Biomarkers assays for T-lymphocyte activation and proliferation applied in a multicenter clinical trial of AEB071 in renal transplantation
J. M. Kovarik, K. Budde, J. Steiger, J. M. Grinyo, F. Straube, A. Groenewegen, A. Vitalit, J. Geissler, J. Klupp, M. J. BartenAnn Transplant 2008; 13(1): 42-42 :: ID: 880209
Abstract
Background: AEB071 is a novel protein kinase C inhibitor that blocks the activation of T-lymphocytes.
Material/Methods: In a multicenter phase 2 trial, de novo kidney transplant recipients received AEB071 200 mg twice-daily with basiliximab, tacrolimus, and corticosteroids. We collected blood samples in a subset of 28 patients before transplantation and on day 8 posttransplantation to quantify biomarkers of T-lymphocyte activation and proliferation. The study sponsor provided analytical reagents and trained the site personnel. Within 16 hours of collection, heparinized blood was stimulated with PMA and anti-CD28 for T-cell activation and frozen. For T-cell proliferation, heparinized blood was stimulated with lectin followed by addition of 3H-thymidine and then frozen. Frozen samples were sent to the analyzing laboratory via a central collection agency. T-cell activation was quantified by flow cytometry to yield the percent T-cells double positive for IL2 and TNF (IL2+TNF+). T-cell proliferation was quantified by scintillation counting of thymidine uptake. Data are medians [interquartile range].
Results: Before transplantation, the percent IL2+TNF+ T-cells was 2.0 [0.5-5.9]%. This was reduced by 100% posttransplant to 0 [0-0.1]% (p=0.002). Thymidine uptake was 5.0 [2.9-14.7] cpm - 103 before transplantation. This was reduced by 84% posttransplant to 0.7 [0.4-1.4] cpm - 103 (p=0.003).
Conclusions: Despite the complexity of these assays, they were successfully implemented in the context of an international clinical trial. These biomarkers yielded individualized, quantitative evidence that T-cell activation and proliferation were inhibited by the immunosuppressive regimen and will contribute to the overall interpretation of the study results.
Keywords: resistant bacteria, T-Lymphocytes, Tacrolimus
In Press
08 Mar 2024 : Original article
Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...Ann Transplant In Press; DOI: 10.12659/AOT.943532
14 Mar 2024 : Original article
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort StudyAnn Transplant In Press; DOI: 10.12659/AOT.943652
14 Mar 2024 : Case report
Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...Ann Transplant In Press; DOI: 10.12659/AOT.942358
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860